sunovion | Innovative Treatments, Science and Technology

Keyword	CPC	PCC	Volume	Score	Length of keyword
sunovion	1.32	0.4	6465	40	8

Keyword	CPC	PCC	Volume	Score
sunovion	0.86	0.5	7965	69

Search Results related to sunovion on Search Engine

Innovative Treatments, Science and Technology | Sumitomo …
sumitomo-pharma.com

https://www.us.sumitomo-pharma.com/

WEBWe drive innovative treatments, science, and technology to address patient needs in the critical areas of psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapy. Learn More. Discovering Sumitomo Pharma …

DA: 65 PA: 74 MOZ Rank: 12

Sunovion - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Sunovion

WEBWebsite. http://www.sunovion.com. On July 1, 2023, Sunovion Pharmaceuticals Inc. became part of Sumitomo Pharma America, Inc., [1] a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry and neurology, oncology, urology ...

DA: 25 PA: 1 MOZ Rank: 85

Sunovion: creating therapies to help transform people's lives
sunovion.com

https://www.sunovion.com/?_hsenc=p2ANqtz-8PIhy3sh2lxH2pTYUOXBTlZw5fj3FGNoMyucapt548vH95I6nhKvAhjaUwEOs5MQ6T8UUV2K-c6jVae6JsraHyMe9V1Q

WEBAt Sunovion, we strive to serve and create value for patients every day. By developing innovative therapies that treat serious Central Nervous System (CNS) conditions, science leads the way—guiding us to a healthier tomorrow.

DA: 97 PA: 84 MOZ Rank: 79

Sumitomo Pharma Subsidiary Companies in the U.S., Including ... - Sunovion
sunovion.com

https://news.sunovion.com/press-releases/press-releases-details/2023/Sumitomo-Pharma-Subsidiary-Companies-in-the-U.S.-Including-Sunovion-to-Combine-and-Form-Sumitomo-Pharma-America/default.aspx

WEBMonday, April 3, 2023 10:08 am. MARLBOROUGH, Mass.-- (BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced today that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc ...

DA: 47 PA: 32 MOZ Rank: 12

Sunovion Pharmaceuticals | LinkedIn
linkedin.com

https://www.linkedin.com/company/sunovion-pharmaceuticals-inc-

WEBMarlborough, MA 55,097 followers. Our vision is to lead the way to a healthier world. View all 1,151 employees. About us. We are now Sumitomo Pharma America (SMPA), a science-based,...

DA: 76 PA: 76 MOZ Rank: 62

Sunovion Pharmaceuticals Inc. - Sunovion and Otsuka Initiate …
sunovion.com

https://news.sunovion.com/press-releases/press-releases-details/2023/Sunovion-and-Otsuka-Initiate-Clinical-Development-of-Ulotaront-for-the-Treatment-of-Generalized-Anxiety-Disorder/default.aspx

WEBApr 26, 2023 · Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder. Wednesday, April 26, 2023 8:00 am. –Approximately 7.5 Million People in The U.S. Are Living …

DA: 85 PA: 17 MOZ Rank: 52

Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter …
sumitomo-pharma.com

https://www.us.sumitomo-pharma.com/newsroom/press-releases/Sunovion-Sumitomo-Dainippon-Pharma-and-Otsuka-Enter-Worldwide-Development-and-Commercialization-Collaboration/

WEBAbout Sunovion. Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s vision is to lead the way to a healthier world.

DA: 77 PA: 62 MOZ Rank: 4

Sunovion Pharmaceuticals Inc. - Otsuka and Sunovion Initiate …
sunovion.com

https://news.sunovion.com/press-releases/press-releases-details/2022/Otsuka-and-Sunovion-Initiate-Clinical-Development-of-Ulotaront-for--the-Adjunctive-Treatment-of-Major-Depressive-Disorder/default.aspx

WEB– December 1, 2022 – Otsuka Pharmaceutical Development & Commercialization, Inc.(Otsuka) and Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the first patient has been enrolled in a Phase 2/3 clinical study to evaluate ulotaront (SEP-363856), a trace amine-associated receptor 1 (TAAR1) agonist with 5HT 1A agonist activity, as ...

DA: 45 PA: 74 MOZ Rank: 63

SUNOVION: Announces U.S. FDA Approval of KYNMOBI™ …
fdahealthnews.com

https://fdahealthnews.com/stories/537868581-sunovion-announces-u-s-fda-approval-of-kynmobi-apomorphine-hydrochloride-sublingual-film-for-the-treatment-of-parkinson-s-disease-off-episodes

WEBMay 22, 2020 · Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) has approved KYNMOBI™ (apomorphine HCI) sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD).

DA: 78 PA: 62 MOZ Rank: 67

Sunovion Announces Topline Results from Global Phase 2 Study of …
sumitomo-pharma.com

https://www.us.sumitomo-pharma.com/newsroom/press-releases/Sunovion-Announces-Topline-Results-from-Global-Phase2-Study-of-SEP-4199-in-Patients-with-Bipolar-I-Depression/

WEBMARLBOROUGH, Mass., June 29, 2021 at 9:00 AM EDT (BUSINESS WIRE) — Sunovion Pharmaceuticals Inc. (Sunovion) today announced topline results from study SEP380-201, a global, multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy, safety, and tolerability of treatment with SEP-4199, an ...

DA: 58 PA: 8 MOZ Rank: 91